...
首页> 外文期刊>CNS neuroscience & therapeutics. >CIQ, a positive allosteric modulator of GluN2C/D‐containing N‐methyl‐d‐aspartate receptors, rescues striatal synaptic plasticity deficit in a mouse model of Parkinson's disease
【24h】

CIQ, a positive allosteric modulator of GluN2C/D‐containing N‐methyl‐d‐aspartate receptors, rescues striatal synaptic plasticity deficit in a mouse model of Parkinson's disease

机译:CIQ是含有GluN2C / D的N-甲基-d-天冬氨酸受体的正变构调节剂,可在帕金森氏病小鼠模型中挽救纹状体突触可塑性

获取原文
           

摘要

Summary AimsTo investigate if CIQ, a positive allosteric modulator of N -methyl- d -aspartate receptors (NMDARs) containing GluN2C/D subunits, rescues the loss of long-term potentiation (LTP) and forelimb-use asymmetry in a mouse model of Parkinson's disease (PD). MethodsWe have used electrophysiology in brain slices and the cylinder test to examine the effect of CIQ on glutamatergic synaptic transmission, synaptic plasticity, and forelimb-use in the unilateral 6-hydroxydopamine-lesion mouse model of PD. ResultsCIQ, applied in the perfusion solution, reversibly reduced glutamatergic synaptic transmission in the dopamine-depleted striatum and had no effect in the dopamine-intact striatum. LTP, a dopamine- and NMDAR-dependent form of synaptic plasticity, was induced in the dopamine-intact striatum but was lost in the dopamine-depleted striatum. This impaired LTP was restored in the presence of CIQ applied in the perfusion solution. This treatment, however, prevented LTP induction in control slices. In brain slices from mice which received single and chronic intraperitoneal injections of CIQ, LTP was restored in the dopamine-depleted striatum and unaffected in the dopamine-intact striatum. Forelimb-use asymmetry, a test which assesses deficits in paw usage in the unilateral lesion model of PD, was reversed by systemic chronic treatment with CIQ. ConclusionA positive allosteric modulator of GluN2C/D-containing NMDARs rescues LTP and forelimb-use asymmetry in a mouse model of PD. This study proposes GluN2D as a potential candidate for therapeutic intervention in PD.
机译:摘要目的研究CIQ是一种含有GluN2C / D亚基的N-甲基-d-天冬氨酸受体(NMDARs)的正变构调节剂,能否挽救帕金森氏症小鼠模型的长期增强(LTP)和前肢不对称性丧失。疾病(PD)。方法我们使用脑切片的电生理学和圆柱体测试来检验CIQ对PD单侧6-羟基多巴胺损伤小鼠模型中谷氨酸能突触传递,突触可塑性和前肢使用的影响。结果灌注溶液中使用的CIQ可逆地减少了贫多巴胺的纹状体中谷氨酸能突触的传递,而对多巴胺完整的纹状体没有影响。 LTP是一种多巴胺和NMDAR依赖性的突触可塑性,在完整的多巴胺纹状体中被诱导,但是在消耗多巴胺的纹状体中丢失。在灌注溶液中使用CIQ的情况下,恢复了受损的LTP。然而,这种处理阻止了对照切片中的LTP诱导。在接受CIQ单次和长期腹膜内注射的小鼠的脑切片中,LTP在多巴胺缺乏的纹状体中恢复,而在多巴胺完整的纹状体中不受影响。 CIQ的系统性慢性治疗可以逆转前肢使用的不对称性,该测试用于评估PD单侧病变模型中爪使用的缺陷。结论含有GluN2C / D的NMDAR的正变构调节剂可以挽救PD小鼠模型的LTP和前肢使用不对称性。这项研究建议GluN2D作为PD治疗干预的潜在候选人。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号